Cargando…

Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice

BCG is currently the only licensed vaccine against tuberculosis (TB) and confers protection against meningitis and miliary tuberculosis in infants, although pulmonary disease protection in adults is inconsistent. Recently, promising HIV-1 immunogens were developed, such as the T-cell immunogens “tHI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kilpeläinen, Athina, Saubi, Narcís, Guitart, Núria, Moyo, Nathifa, Wee, Edmund G., Ravi, Krupa, Hanke, Tomáš, Joseph, Joan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530512/ https://www.ncbi.nlm.nih.gov/pubmed/31156614 http://dx.doi.org/10.3389/fimmu.2019.00923

Ejemplares similares

Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice
por: Kilpeläinen, Athina, et al.
Publicado: (2019)

Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice
por: Saubi, Narcís, et al.
Publicado: (2020)

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice
por: Chen, Chun-Wei, et al.
Publicado: (2022)

Preclinical development of BCG.HIVA(2auxo.int), harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
por: Mahant, Aakash, et al.
Publicado: (2017)

MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice
por: Broset, Esther, et al.
Publicado: (2019)

Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines
por: Wee, Edmund G., et al.
Publicado: (2021)

Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA
por: Moyo, Nathifa, et al.
Publicado: (2018)

Pre-Clinical Development of BCG.HIVA(CAT), an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG
por: Saubi, Narcís, et al.
Publicado: (2012)

Newborn Mice Vaccination with BCG.HIVA(222) + MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes
por: Saubi, Narcís, et al.
Publicado: (2011)

A rare case of bilateral optic neuritis post-Covishield (ChAdOx1-S [recombinant]) vaccination
por: Natung, Tanie, et al.
Publicado: (2023)

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice
por: Chen, Chun-Wei, et al.
Publicado: (2023)

Engineering new mycobacterial vaccine design for HIV–TB pediatric vaccine vectored by lysine auxotroph of BCG
por: Saubi, Narcís, et al.
Publicado: (2014)

Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice
por: Zhang, Beibei, et al.
Publicado: (2023)

Emergence of COVID-19 variants among ChAdOx1 nCoV-19 (recombinant) vaccine recipients
por: Vaishya, Raju, et al.
Publicado: (2021)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
por: Ogbe, Ane, et al.
Publicado: (2022)

Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines
por: Chen, Chun-Wei, et al.
Publicado: (2020)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023)

Adenovirus Transcriptome in Human Cells Infected with ChAdOx1-Vectored Candidate HIV-1 Vaccine Is Dominated by High Levels of Correctly Spliced HIVconsv1&62 Transgene RNA
por: Matthews, David A., et al.
Publicado: (2023)

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1
por: Wee, Edmund G., et al.
Publicado: (2019)

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1
por: Wee, Edmund G., et al.
Publicado: (2022)

Molecular Characterization of Heterologous HIV-1gp120 Gene Expression Disruption in Mycobacterium bovis BCG Host Strain: A Critical Issue for Engineering Mycobacterial Based-Vaccine Vectors
por: Joseph, Joan, et al.
Publicado: (2010)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
por: Folegatti, Pedro M., et al.
Publicado: (2019)

Inflammatory myositis after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
por: Beavis, Ashley C., et al.
Publicado: (2023)

P17-17. Newborn mice vaccination with rBCG:HIVA + MVA:HIVA enhances HIV-1-specific immune responses. Influence of age and immunization routes
por: Saubi, N, et al.
Publicado: (2009)

P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice
por: Stutz, H, et al.
Publicado: (2009)

Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice
por: Chapman, Rosamund, et al.
Publicado: (2013)

Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens
por: Antrobus, Richard D, et al.
Publicado: (2014)

COVID‐19 vaccine (ChAdOx1 nCoV‐19 Corona virus vaccine (Recombinant) – COVISHIELD related MS relapse
por: Mathew, Thomas, et al.
Publicado: (2021)

Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP
por: Costa Clemens, Sue Ann, et al.
Publicado: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
por: Moyo, Nathifa, et al.
Publicado: (2017)

Pre-clinical development of BCG.HIVA(CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine
por: Saubi, N, et al.
Publicado: (2012)

Correction: Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice
por: Chapman, Rosamund, et al.
Publicado: (2013)

Identifying the Important HIV-1 Recombination Breakpoints
por: Archer, John, et al.
Publicado: (2008)

The Use of Directed Evolution to Create a Stable and Immunogenic Recombinant BCG Expressing a Modified HIV-1 Gag Antigen
por: Chapman, Rosamund, et al.
Publicado: (2014)

Expression of Chimeric HPV-HIV Protein L1P18 in Pichia pastoris; Purification and Characterization of the Virus-like Particles
por: Eto, Yoshiki, et al.
Publicado: (2021)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gel8al7redc924g8m9fcp6pobf